Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (56877)	7/28/2000 11:03:37 AM
From: Tom Allinder	Read Replies (1) \| Respond to of 150070

Here is the meat and potatoes of the story on DNAP: Opportunities abound While a gene itself can't be patented, a genetic treatment method or diagnostic process can be. A number of firms hope to do just that, then sell or lease the patent to pharmaceutical giants with the resources to turn them into drugs. AmeriPath (Nasdaq: PATH) and Genomics plan to establish a kind of genetic library. "Researchers can come to us and say 'I need 100 colon cancers from the state of Florida,' and we will be able to get them DNA from those types of cases," AmeriPath's Smith said. "We are developing a database of information and it's the size and diversity of the database of information together with the way the information is collected and the way that information is presented that will make a database valuable to researchers," added Dr. Michael J. Pellini, president and COO of Genomics Collaborative. Drug companies seeking to develop specially targeted potions would find such information of great value, he said. Others, however, see the opportunity in the reverse order: discovering gene function by analyzing drugs already on the market. DNA Print Genomics Inc. of Sarasota is going the Sherlock Holmes route of deductive reasoning. Founded by molecular biologist Tony Frudakis and mathematician Myung Ho Kim, the first step is developing a set of algorithms to isolate genetic patterns by examining the DNA of people with adverse liver reactions to a commonly prescribed anti-cholesterol medicine. In that fashion, the company believes it will find both the complex of genes and environmental factors that can predict whether a person's liver will be at risk from the medication. With this information in hand, drugs can be tailored to a person's genetic map. The company plans to make money by patenting the genetic pattern associated with each drug reaction. While these may be licensed to pharmaceutical firms, the company also will charge doctors a fee for running their patients' profiles through its database. "A good analogy is that the human genome project is like a dictionary. It is up to each company to learn how to make sentences, paragraphs and books that make sense," Frudakis said. "The worldwide government made sure that no one can own the dictionary. But you can write a book, and it's your book." Tom

To: StocksDATsoar who wrote (56877)	7/28/2000 11:09:08 AM
From: dan oreilly	Respond to of 150070

NICE find speedy...woulda been nice IF DNAP had also gotten the ticker symbol in the article....still nice article

To: StocksDATsoar who wrote (56877)	7/28/2000 11:29:24 AM
From: Jim Bishop	Respond to of 150070

DNAP IMO a ground floor opportunity, that is still on the ground floor. Downside, negligible.. ...hell go back 6 months, or a year, or whatever it was on this thread, to when SSP and I were talking about CLYC when it was a shell.....trading at these levels Then repeat, over and over, one of my favorite sayings: You can't fall far........from a basement window. You can't fall far........from a basement window. You can't fall far........from a basement window. You can't fall far........from a basement window.